Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 5/20 | 1.00 |
| ▸ | PIK3C2G | O75747 | 5/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 4/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 2/20 | 1.00 |
| ▸ | PI4KB | Q9UBF8 | 13/20 | 0.73 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14851574 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3C2GPIK3CGPIK3CAPI4KB | |
| SCHEMBL14851892 | 0.93 | PIK3CD (0.87) | PIK3CDPIK3C2GPIK3CGPIK3CAPI4KB | |
| SCHEMBL24535575 | 0.93 | PIK3CD (0.86) | PIK3CDPIK3C2GPIK3CGPIK3CAPI4KB | |
| SCHEMBL22336531 | 0.92 | PIK3CD (0.85) | PIK3CDPIK3C2GPIK3CGPIK3CAPI4KB | |
| SCHEMBL24535456 | 0.91 | PIK3CD (0.84) | PIK3CDPIK3C2GPIK3CGPIK3CAPI4KB | |
| SCHEMBL22338311 | 0.90 | PIK3CD (0.82) | PIK3CDPIK3C2GPIK3CGPIK3CAPI4KB | |
| SCHEMBL14851607 | 0.90 | PIK3C2G (0.82) | PIK3CDPIK3C2GPIK3CGPIK3CAPI4KB | |
| SCHEMBL14851645 | 0.89 | PIK3C2G (0.81) | PIK3CDPIK3C2GPIK3CGPIK3CAPI4KB | |
| SCHEMBL14851641 | 0.89 | PIK3C2G (0.80) | PIK3CDPIK3C2GPIK3CGPIK3CAPI4KB | |
| SCHEMBL22336535 | 0.89 | PIK3CD (0.80) | PIK3CDPIK3C2GPIK3CGPIK3CAPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243464-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-07-31 | — | — | US | claimed |
| EP-4587557-A2 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | Vertex Pharmaceuticals Incorporated (US) | 2025-07-23 | — | — | EP | claimed |
| US-20240358767-A1 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-31 | — | — | US | claimed |
| EP-4430163-A2 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | Vertex Pharmaceuticals Incorporated (US) | 2024-09-18 | — | — | EP | claimed |
| WO-2024059776-A2 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-03-21 | — | — | WO | claimed |
| WO-2023081884-A2 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-05-11 | — | — | WO | claimed |
| US-20260028591-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260022345-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-22 | — | — | US | disclosed |
| WO-2025235403-A1 | DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250326725-A1 | PI4-Kinase Inhibitors and Methods of Using the Same | UNIV LELAND STANFORD JUNIOR (US) | 2025-10-23 | — | — | US | disclosed |
| US-12415788-B2 | PI4-kinase inhibitors and methods of using the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250243464-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-07-31 | — | — | US | disclosed |
| EP-4587557-A2 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | Vertex Pharmaceuticals Incorporated (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024059776-A2 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023081884-A2 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20220273624-A1 | NOVEL ANTIVIRAL THERAPIES | NIKLOVIR AB (SE) | 2022-09-01 | — | — | US | disclosed |
| US-20220153711-A1 | P14-Kinase Inhibitors and Methods of Using the Same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-05-19 | — | — | US | disclosed |
| EP-3989971-A1 | NOVEL ANTIVIRAL THERAPIES | Niklovir AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| CN-114174275-A | PI 4-kinase inhibitors and methods of use thereof | 小利兰·斯坦福大学托管委员会 | 2022-03-11 | — | — | CN | disclosed |
| US-20220062243-A1 | P14-Kinase Inhibitors with Anti-Cancer Activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326725-A1 | PI4-Kinase Inhibitors and Methods of Using the Same | PI4KB, PI4KA, PI4K2A | PIK3CD 18/4885PIK3C2G 56/4885PIK3CG 19/4885 |
| US-20220062243-A1 | P14-Kinase Inhibitors with Anti-Cancer Activity | PI4KB, CDKN1A, PI4KA | PIK3CD 158/4885PIK3C2G 542/4885PIK3CG 156/4885 |
| US-20220273624-A1 | NOVEL ANTIVIRAL THERAPIES | HAVCR2, RPL35, MAVS | PIK3CD 4785/4885PIK3C2G 4842/4885PIK3CG 4789/4885 |
| US-12415788-B2 | PI4-kinase inhibitors and methods of using the same | PI4KB, PI4KA, PI4K2A | PIK3CD 18/4885PIK3C2G 56/4885PIK3CG 19/4885 |
| US-20220153711-A1 | P14-Kinase Inhibitors and Methods of Using the Same | PI4KB, PI4KA, PI4K2A | PIK3CD 29/4885PIK3C2G 157/4885PIK3CG 34/4885 |
| US-20260028591-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | IAPP, CTNND1, CTNNBL1 | PIK3CD 1963/4885PIK3C2G 4278/4885PIK3CG 3045/4885 |
| US-20240358767-A1 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | EBP, AKT3, PRKCD | PIK3CD 7/4885PIK3C2G 144/4885PIK3CG 25/4885 |
| US-20250243464-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | IAPP, PNLIP, GPR119 | PIK3CD 485/4885PIK3C2G 2773/4885PIK3CG 675/4885 |
| US-20260022345-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | IAPP, PNLIP, CTNND1 | PIK3CD 2096/4885PIK3C2G 4229/4885PIK3CG 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.